BridgeBio Pharma (BBIO) - News Mentions

Sign up to add (BBIO) to your portfolio and access more historical data.

0 100%
Est. daily news mentions.

Sign up to access historical data

Sign up

Similar companies

Company News Mentions
Amgen
Amgen
AMGN		 0 0%
Gilead Sciences
Gilead Sciences
GILD		 2 0%
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals
CPRX		 0 0%
Inovio Pharmaceuticals
Inovio Pharmaceuticals
INO		 0 100%
Anavex Life Sciences
Anavex Life Sciences
AVXL		 0 0%
BridgeBio Pharma CFO Brian Stephenson sells shares worth $93,136
November 20
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
November 19
BridgeBio Pharma (NASDAQ:BBIO) and International Stem Cell (OTCMKTS:ISCO) Head-To-Head Contrast
November 18
The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically
November 18
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
November 18
State of New Jersey Common Pension Fund D Acquires 9,225 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
November 18
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $45.00
November 17
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – AHA 2024 – Relationship Between CVH and Survival in the Acoramidis Treated Participants within ATTRibute CM
November 17
BBIO – Acoramidis AG10 TTR – AHA 2024 – Evolving Baseline Risk in Patients with ATTR-CM: A Systematic Literature Review of Clinical Trials
November 17
BBIO – Acoramidis AG10 TTR – AHA 2024 – Acoramidis Reduces ACM and CVH: Initial Outcomes from the ATTRibute-CM Open Label Extension Study
November 17
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – AHA 2024 – Costs and healthcare resource utilization in ATTR CM exceeds that of non amyloid heart failure
November 17
Leerink Partnrs Has Pessimistic View of BBIO FY2024 Earnings
November 15
BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
November 13
BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates
November 11
BridgeBio Pharma: Q3 Earnings Snapshot
November 11
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
November 11

Month over Month

Est. daily news mentions.

Oct 2024 0
Sep 2024 0
Aug 2024 0
Jul 2024 0
Jun 2024 0

How often is BridgeBio Pharma mentioned in the news?

BridgeBio Pharma was mentioned an estimated 0 times in online prominent news articles yesterday.

Analyzing News Mentions, how is BridgeBio Pharma performing compared to its industry peers?

BridgeBio Pharma underperforms its industry peers when it comes to News Mentions, ranking dead last.

Has there been an increase or decrease in news mentions of BridgeBio Pharma in the last month?

There has been no significant change in the number of news mentions for BridgeBio Pharma's compared to the last month.

Why is it important to track news mentions for BridgeBio Pharma?

By monitoring mentions in the news for BridgeBio Pharma, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of BridgeBio Pharma, ultimately improving their investment strategies.

Sign up and get more insights on BridgeBio Pharma.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.

Top Stocks

Trending Stocks
Trending Stocks on WallStreetBets
Trending Stocks on Reddit
Top Stocks
Top Stock Performers Today
Bottom Stock Performers Today
Best Airlines Stocks
Best Bank Stocks
Best Semiconductor Stocks
Best Energy Stocks
Best Fintech Stocks
Best Robotics Stocks
Best Insurance Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact